118 related articles for article (PubMed ID: 11700768)
21. Drug prices may be too high despite WTO deal.
Fleck F
Bull World Health Organ; 2003; 81(10):774-5. PubMed ID: 14758442
[No Abstract] [Full Text] [Related]
22. GlaxoSmithKline, under pressure, cuts price of AIDS treatment for poor countries.
Fleck F
Bull World Health Organ; 2003; 81(6):469. PubMed ID: 12894339
[No Abstract] [Full Text] [Related]
23. Drug pricing, AIDS and the developing nations.
Proj Inf Perspect; 2000 Aug; (30):12-5. PubMed ID: 12171009
[TBL] [Abstract][Full Text] [Related]
24. Access to HIV drugs: are we changing the two world paradigm?
Lazzarini Z
Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
[No Abstract] [Full Text] [Related]
25. Affordable drugs for developing countries.
Chong CY
Hong Kong Med J; 2003 Apr; 9(2):148-9. PubMed ID: 12668831
[No Abstract] [Full Text] [Related]
26. Public health and company wealth.
Ford N
BMJ; 2003 Jun; 326(7402):1296. PubMed ID: 12805159
[TBL] [Abstract][Full Text] [Related]
27. More interest in AIDS drug access plan.
Nature; 2001 Jun; 411(6841):984. PubMed ID: 11447609
[No Abstract] [Full Text] [Related]
28. Access to essential drugs.
Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517
[No Abstract] [Full Text] [Related]
29. Senegal cuts deal for low-cost drugs.
IAPAC Mon; 2001 Jan; 7(1):4. PubMed ID: 11305274
[No Abstract] [Full Text] [Related]
30. Anti-AIDS drugs available 'at cost'.
Dickson D
Nature; 2001 Mar; 410(6826):289. PubMed ID: 11268163
[No Abstract] [Full Text] [Related]
31. Anatomy of a successful campaign to lower AIDS drug prices.
AIDS Policy Law; 2003 May; 18(10):7. PubMed ID: 12809098
[No Abstract] [Full Text] [Related]
32. Drug pricing. AHF to file suit against Glaxo for African AIDS-related deaths.
AIDS Policy Law; 2003 Dec; 18(22):5. PubMed ID: 14974398
[No Abstract] [Full Text] [Related]
33. Drug companies should cut prices for developing countries, says G8 report.
Walgate R
Bull World Health Organ; 2003; 81(1):72-3. PubMed ID: 12640481
[No Abstract] [Full Text] [Related]
34. Health, trade, and industry officials set to debate access to essential drugs.
Kapp C
Lancet; 2001 Apr; 357(9262):1105. PubMed ID: 11297977
[No Abstract] [Full Text] [Related]
35. Therapies. The high cost of poverty.
Cohen J
Science; 2002 Jun; 296(5577):2324. PubMed ID: 12089424
[No Abstract] [Full Text] [Related]
36. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
Curti AM
Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
[No Abstract] [Full Text] [Related]
37. Merck broke AIDS drug price promise, says MSF.
Ahmad K
Lancet; 2004 Mar; 363(9412):872. PubMed ID: 15032243
[No Abstract] [Full Text] [Related]
38. Activists dialog about pricing.
AIDS Patient Care STDS; 1999 Apr; 13(4):247. PubMed ID: 10351896
[No Abstract] [Full Text] [Related]
39. "No turning back" on cheap AIDS drugs for poor nations, UN vows.
Silversides A
CMAJ; 2003 Nov; 169(10):1067. PubMed ID: 14609992
[No Abstract] [Full Text] [Related]
40. Access to treatment for HIV/AIDS: a human rights issue in the developing world.
Joni J
Conn J Int Law; 2002; 17(2):273-80. PubMed ID: 12688296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
